These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 37414267

  • 41. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 42. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [Abstract] [Full Text] [Related]

  • 43. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
    Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC.
    Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB, Wang Y, Song QJ, Shen DH.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [Abstract] [Full Text] [Related]

  • 48. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.
    Al Hamed R, Bazarbachi AH, Mohty M.
    Bone Marrow Transplant; 2020 Jan; 55(1):25-39. PubMed ID: 31089285
    [Abstract] [Full Text] [Related]

  • 49. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
    Dutta R, Miao SY, Phan P, Fernandez-Pol S, Shiraz P, Ho D, Mannis GN, Zhang TY.
    J Med Case Rep; 2021 Mar 28; 15(1):170. PubMed ID: 33773605
    [Abstract] [Full Text] [Related]

  • 50. Toxoplasmic Encephalitis Followed by Primary EBV-Associated Post-Transplant Lymphoproliferative Disorder of the Central Nervous System in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Report.
    Mayumi A, Yamashita T, Matsuda I, Hikosaka K, Fujino S, Norose K, Kato Y, Hirota S, Nakajima T, Ogawa H, Ikegame K.
    Transplant Proc; 2020 Nov 28; 52(9):2858-2860. PubMed ID: 32873410
    [Abstract] [Full Text] [Related]

  • 51. Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder.
    Lee M, Abousaud A, Harkins RA, Marin E, Balasubramani D, Churnetski MC, Peker D, Singh A, Koff JL.
    Curr Oncol Rep; 2023 Aug 28; 25(8):883-895. PubMed ID: 37162742
    [Abstract] [Full Text] [Related]

  • 52. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
    Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.
    Leuk Lymphoma; 2019 Jul 28; 60(7):1693-1696. PubMed ID: 30741059
    [Abstract] [Full Text] [Related]

  • 53. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.
    Stocker N, Labopin M, Boussen I, Paccoud O, Bonnin A, Malard F, Amiel C, Gozlan J, Battipaglia G, Duléry R, Giannotti F, Ruggeri A, Gaugler B, Mohty M, Brissot E.
    Bone Marrow Transplant; 2020 Mar 28; 55(3):586-594. PubMed ID: 31562397
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Clinical Post-Transplant Lymphoproliferative Disorders.
    Aghsaeifard Z, Alizadeh R.
    Cardiovasc Hematol Disord Drug Targets; 2022 Mar 28; 22(2):96-103. PubMed ID: 35927798
    [Abstract] [Full Text] [Related]

  • 56. Successful Treatment of Central Nervous System Involvement in Posttransplant EBV-related Lymphoproliferative Disease With Intrathecal Rituximab Therapy.
    Aslan F, Güler S, Sezgin Evim M, Aslier M, Yazici Z, Öztürk Nazlioğlu H, Meral Güneş A.
    J Pediatr Hematol Oncol; 2023 Jul 01; 45(5):e628-e630. PubMed ID: 36730621
    [Abstract] [Full Text] [Related]

  • 57. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J.
    Leuk Lymphoma; 2019 Jan 01; 60(1):142-150. PubMed ID: 29966464
    [Abstract] [Full Text] [Related]

  • 58. Clinical value of plasma and peripheral blood mononuclear cells Epstein-Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation.
    Zhou X, Lu X, He J, Xu Z, Li Q, Ye P, Zhong Z, Shi W, Yan H, You Y, Hu Y, Wang H.
    Front Cell Infect Microbiol; 2022 Jan 01; 12():980113. PubMed ID: 36189344
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ.
    Biol Blood Marrow Transplant; 2015 Dec 01; 21(12):2185-2191. PubMed ID: 26253005
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.